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Background: Drug metabolism via the cytochrome P450 (CYP450) system has emerged as an important
determinant in the occurrence of several drug interactions (adverse drug reactions, reduced pharmacological effect,
drug toxicities). In particular, CYP3A4 and CYP3A5 (interacting with more than 60% of licensed drugs) exhibit the
most individual variations of gene expression, mostly caused by single nucleotide polymorphisms (SNPs) within the
regulatory region of the CYP3A4 and CYP3A5 genes which might affect the level of enzyme production.
In this study, we sought to improve the performance of sensitive screening for CYP3A polymorphism detection in
twenty HIV-1 infected patients undergoing lopinavir/ritonavir (LPV/r) monotherapy.
Methods: The study was performed by an effective, easy and inexpensive home-made Polymerase Chain Reaction
Direct Sequencing approach for analyzing CYP3A4 and CYP3A5 genes which can detect both reported and unreported
genetic variants potentially associated with altered or decreased functions of CYP3A4 and CYP3A5 proteins. Proportions
and tests of association were used.
Results: Among the genetic variants considered, CYP3A4*1B (expression of altered function) was only found in 3
patients (15%) and CYP3A5*3 (expression of splicing defect) in 3 other patients (15%). CYP3A5*3 did not appear to
be associated with decreased efficacy of LPV/r in any patient, since none of the patients carrying this variant showed
virological rebound during LPV/r treatment or low levels of TDM. In contrast, low-level virological rebound was
observed in one patient and a low TDM level was found in another; both were carrying CYP3A4*1B.
Conclusions: Our method exhibited an overall efficiency of 100% (DNA amplification and sequencing in our group of
patients). This may contribute to producing innovative results for better understanding the inter-genotypic variability
in gene coding for CYP3A, and investigating SNPs as biological markers of individual response to drugs requiring
metabolism via the cytochrome P450 system.
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Table 1 Characteristics of analyzed patients
Sex (male) 13/20 (65%)
Age (median years) 46 (IQ range 44–50)
CD4+ count (median cells/mm3) 761 (IQ range 474–833)
N. low level Virological Rebound 5/20 (25%)
LPV/r punctual TDM (median μg/ml) 5.096 (IQ range 1.748–6.996)
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Genetic polymorphisms are well-recognized sources of
individual differences in disease risk and treatment re-
sponse. In fact, a high number of associations between
human genetic variants and predisposition to adverse
events have been described for different kinds of drugs,
interacting with hundreds of proteins like receptors,
transporters and metabolizing enzymes [1,2].
Cytochrome P450 (CYP450) is a family of isoenzymes
responsible for the biotransformation of several drugs.
Therefore, drug metabolism via the cytochrome P450
system has emerged as determinant in the occurrence of
several drug interactions (drug toxicities, reduced pharma-
cological effect and adverse drug reactions) [3]. CYP3A4
and CYP3A5, representing 65% of isoforms in the cyto-
chrome p450 enzyme family, interact with more than 60%
of licensed drugs. Individual variations in single nucleotide
polymorphisms (SNPs) within the regulatory genes of
CYP3A4 and CYP3A5 might affect the level of enzyme
production [4-6].
While the majority of SNPs have no biological conse-
quences, a fraction of gene substitutions have functional
significance and provide the basis for the diversity found
among humans. So far, associations between human
CYP3A4 and CYP3A5 genetic variants and predisposition
to adverse drug reactions (ADRs) or therapy failure have
often been hypothesized and described, mainly in HIV-
infected patients treated with protease inhibitors (PI)
whose metabolism is affected by induction or inhibition of
CYP3A [7-11]. However, most studies published to date
suffer from limitations, often represented by small study
size or ethnic bias. This is probably due to the unavaila-
bility of robust, automated and inexpensive methods for
detecting both known and unknown CYP3A genetic poly-
morphisms. Thus, the objective of this study was to
develop and validate an effective, easy and inexpensive
homemade Polymerase Chain Reaction Direct Sequencing
(PCR-DS) approach for analyzing CYP3A4 and CYP3A5
genes, and detecting both reported and unreported ge-
netic variants that may potentially be associated with
altered or decreased functions of CYP3A4 and CYP3A5
proteins. Aiming to validate the method and avoid con-
founding drug - drug interactions, we included a homoge-
neous group of HIV patients undergoing steady treatment
with RTV-boosted lopinavir (LPV/r) alone (LPV/r- mono-
therapy; pill dose: 200 mg lopinavir/50 mg Ritonavir, two
pills BID).
Methods
Patients included and data collected
We analyzed 20 Caucasian HIV-infected patients under-
going treatment with LPV/r monotherapy with undetec-
table HIV-RNA (<40 copies/ml); all patients were in
clinical follow-up at the Spallanzani Institute outpatientclinic. The ethics committee of the Lazzaro Spallanzani
National Institute for Infectious Diseases review board
approved the study and all patients gave written in-
formed consent for inclusion. The patients’ characte-
ristics are described in Table 1. In particular, virological
rebound of HIV-RNA over the limit of detection (>40
copies/ml) and therapeutic drug monitoring (TDM)
were used as indicators of treatment failure to evidence
the possible reduction of LPV levels.
Genomic DNA isolation
In house methodologies based upon PCR and direct
sequencing of CYP3A4 and CYP3A5 exons and flanking
sequences (localized on human chromosome 7q21) were
developed and optimized. Genomic DNA was extracted
directly from 200 μl of whole blood using a commercially
available kit (QIAamp DNA Mini Kit, Qiagen, Hilden,
Germany) according to the manufacturer’s instruction.
PCR amplifications
Primers for PCR were designed using the Primer-BLAST
software developed at NCBI [12]. PCR primers were de-
signed with a melting temperature between 57°C – 63°C
(optimum at 60°C). The length of the primers was de-
signed between 15–25 nucleotides with an optimum of 20
nts. The desired length of the PCR products was between
800–1500 bps. The primer had to have at least 2 total mis-
matches with unintended targets, including at least 2 mis-
matches within the last 5 bps at the 3′ end. The design of
PCR primers in repeat regions was avoided. We selected
homemade primers to amplify part of the 5′ upstream re-
gion of CYP3A4 [GenBank: D11131.1] and all exons with
flanking intronic regions of both CYP3A4 [GenBank:
AF209389.1] and CYP3A5 [GenBank: NG_007938.1]. The
primer sets and PCR conditions used are shown in Table 2.
The conditions for PCR amplification consist of an initial
denaturation step at 93°C for 12 min followed by 40 cycles
of 30 s of denaturation at 94°C, 30 s annealing at varying
temperatures (refer to Table 2 for specific annealing tem-
peratures), and a 2.30 min extension at 72°C with a final
extension at 72°C for 10 min. The PCR reaction was
carried out in 50 μl of solution using the following
reaction mix: 5 μl of GeneAmp 10X PCR Buffer (Applied
Biosystem, Foster City, CA, USA), 3 μl of 25 mM MgCl2
solution (Applied Biosystem), 33.95 μl of Dnase Rnase free
water, 0.75 μl of each primer at a concentration of 10 μM,
Table 2 Sequence and location of PCR and sequencing primers









A 5′ Proximal Region A1: GGTCTGTCTGTCTGGGTATGC 296 61
A2: CTCACCACACACTGACCTGCT
B EXON 1 (nt 1–71) B1: AGAACCCAGAACCCTTTGGAC 1 1137 59
B2: GTGCTCCTCTATCTGTGAGTA 78
C EXON 2 (nt 4004–4097) C1: GCTCTCAGTGACCCTCTGTG 3532 1192 59
C2: AACCCCTTTGTTCTGTCTCTCA 4723
D EXON 3 (nt 6009–6061) D1: CCCTGGTGTCTGTACTTTCCA 5529 1200 59
D2: TCCCAGCCTAGTTCAGACTGT 6728
E EXON 4 (nt 11502–11601) E1: ATATCCACGTATGCACCACCC 11185 841 59
E2: GAGCCACATGGAGACAGAGT 12025
F EXONS 5/6 (nt 13956–14069) (nt 14335−14423) F1: CGACATCAGGGTCTCCTGAAC 13720 933 59
F2: GATATGTAAACCCTGGCCCCT 14652
G EXON 7 (nt 15689–15837) G1: CTGTTTGTCTGTCTTGACTGGA 15585 998 61
G2: GCTGTTCAAGAAATAGTAGGTAGTC 16582
H EXON 8 (nt 16932–17059) H1: TTGAGCTTCAGATTATGATTTGGG 16593 956 60
H2: CTGGCTATCATGTGAGATGGC 17548
I EXON 9 (nt 17744–17810) I1: AGCCATCTCACATGATAGCCA 17527 990 57
I2: CTTGGTGGCTTGTAATTGACC 18516
J EXON 10 (nt 20166–20326) J1: TGGGGGAGAGTACTACCTCATA 19785 952 60
J2: AAGAGCCAATTCCTGTGTCCAT 20736
K EXON11 (nt 21912–22138) K1: TTCCCGAATGCTTCCCACCT 21691 917 59
K2: ATGCTACTGTACCGATGTAATGC 22607
L EXON 12 (nt 23198–23360) L1: GGGGTGGCCCCTAAGTAAGA 23109 910 57
L2: TTGGGTTGAAAAGGAGCCCA 24018
M EXON 13 (nt 25950–26502) M1: TGACTCTTCAAAAACAGTTTGCCA 25518 1099 59
M2: AGTTCTGACAAAGGCCCCAC 26502
CYP3A5 gene
N EXON 1 (5001–5173) N1: TAGAATGAAGGCAGCCATGGAG 4723 1032 60
N2: GGGGATTTTCAGGGGCATGG 5774
O EXON 2 (8791–8884) O1: GCTGGTTCTTCTGCACACAATC 8022 964 61
O2: GAAACCTCAGAACTCCCTCCC 8985
P EXON 3 (10414–10466) P1: ATGGAGAGTGGCATAGGAGAT 9878 1177 59
P2: TGTGGTCCAAACAGGGAAGAGAT 11054
Q EXON 4 (12320–12419) Q1: TGTCACCAGGTATCGAGGTCT 11062 1367 60
Q2: GATGCTTACCCTTCGATTTGTGA 12428
R EXONS 5/6 (17934–18047) (18310–18398) R1: CGCCCCACATACACTCAGAA 17746 1184 57
R2: GGCTTGCTCTACACATAGCAT 18929
S EXON 7 (19685–19833) S1: ATAGGGCCAGCTCCATCACTG 19492 1193 60
S2: TTCTGAGTCTTTGGAGTGACCA 20684
T EXONS 8/9 (20904–21031) (22117–22183) T1: GGCCTGAAAGAAGGGCAAAC 20750 1478 57
T2: TCTTAGTGTCCCCGCCAGTA 22228
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Table 2 Sequence and location of PCR and sequencing primers (Continued)
U EXON 10 (24340–24500) U1: AGGATCATTCAAGGCACACACC 24009 1179 61
U2: GCCTTGCTGCTGCCTTGCAG 25188
V EXON 11 (32220–32446) V1: ACCTACCTATGATGCCGTGG 32225 880 57
V2: GAGGACCTGTGCTGTCTTGT 33104
W EXON 12 (34767–34926) W1: GCAGGATTTCAATGACCAGCC 34619 1173 59
W2: CCCCCTGCCTGAATACACAC 35792
Y EXON 13 (36599–36809) Y1: GGGTTCAACTGGGAAGGGTT 36118 1058 57
Y2: GTGTGCAGGATGGCATCAGA 37175
PCR reactions are named in alphabetical order. The same primers are used for PCR and sequencing reactions.
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Taq Gold DNA Polymerase (5 u/μl, Applied Biosystems).
See Table 2 for primer sequences and PCR annealing. In
each PCR reaction, a negative control sample was included
to ensure that no contamination of samples occurred du-
ring the analyses. The PCR products were electrophoresed
on agarose gel to verify successful PCR and the absence of
primer dimers. The products obtained were then subse-
quently used as templates for the sequencing reactions.
DNA sequencing
The PCR products were purified with the PCR Cleanup
KIT (Abbott, Wiesbaden, Germany) and then sequenced
on both strands using the BigDye® Terminator Cycle Se-
quencing Kit v.3.1 (Applied Biosystems). The reaction mix-
ture for the sequencing reaction contained 4 μl ABI PRISM
Big Dye Terminator (Applied Biosystem), 3.8 μl water, 4 μl
BigDye® TerminatorBuffer 5X1 (Applied Biosystems), 3.2 μl
primer (1 pmol) and 5 μl of purified cDNA (40 ng), for a
total volume of 20 μl. The sequencing conditions were:
one cycle at 96°C for 3 min and 25 cycles (96°C for 30 s,
50°C for 10 s, 60°C for 4 min). Sequencing primers were
the same of PCR reactions (see Table 2). The sequence
products were purified by gel filtration chromatography
using Sephadex G-50 resin (Sigma-Aldrich, Missouri,
United States), in order to eliminate excess primers and/
or unincorporated dideoxynucleotides (dNTPs), and then
separated on an automated sequencer (ABI PRISM-3130
Genetic Analyzer, Applied Biosystems).
Results
By using SeqScape v.2.6 software we observed that all
generated CYP3A4 and CYP3A5 DNA sequences matched
the reference consensus sequences perfectly (see Figure 1).
We initially focused our analysis on genetic variants
significantly associated with altered or decreased protein
expression (for CYP3A4: CYP3A4*1B, CYP3A4*2, CYP
3A4*4, CYP3A4*5, CYP3A4*6, CYP3A4*8, CYP3A4*11,
CYP3A4*12, CYP3A4*13, CYP3A4*16, CYP3A4*17,
CYP3A4*18; for CYP3A5: CYP3A5*3, CYP3A5*5,
CYP3A5*6, CYP3A5*8, CYP3A5*9, CYP3A5*10) intwenty HIV-1 infected patients undergoing LPV/r
monotherapy, (Table 3) [4,12,13].
Patients started LPV/r monotherapy after achieving viral
suppression (Table 1). Six patients interrupted LPV/r for
viral rebound after a median time of 7 months.
Among the genetic variants considered, CYP3A4*1B
(expression of altered function) was only found in three pa-
tients (15%) and CYP3A5*3 (expression of splicing defect)
in three other patients (15%) by proportions and tests of
association [8,12,14,15]. CYP3A5*3 did not appear to be
associated with decreased efficacy of LPV/r in any of the
patients. Indeed, none of the patients carrying this variant
showed virological rebound during LPV/r treatment or
low level of TDM. In contrast, low-level virological re-
bound was observed in one patient and a low TDM level
(1.748 μg/ml vs. a mean of 4.719, IQ range 3.008-6.996) in
a second patient; both were carrying CYP3A4*1B.
Moreover, many previously unreported SNPs were ob-
served, and data collection in a dedicated database is in
progress. Therefore, our PCR-DS method is able to detect
clinically relevant substitutions occurring in CYP3A4 and
CYP3A5 without using commercial kits, and with a con-
siderable reduction of costs. In addition, the PCR primers
were also designed to cover a large part of the flanking in-
tronic sequence (see Figure 1). Indeed, by displaying the
entire gene sequence it is possible to investigate new poly-
morphisms which are potentially able to modulate CYP3A
gene expression and enzyme activity, and thus affect drug
metabolism.
Our protocols showed an overall efficiency of 100% in
terms of DNA amplification and sequencing. Primers were
selected with similar or identical annealing temperatures
to perform the screening of several exons in the course
of one analysis in order to reduce the number of PCR
machines involved in the process and save laboratory
time. No primer interactions (namely primer dimers) were
observed.
Discussion
The ability of even a single cytochrome P450 isoenzyme
to metabolize many drugs may be responsible for drug-
Figure 1 Representative scheme of PCR and sequencing products. (a) CYP3A4 gene. (b) CYP3A5 gene. In red are evidence all CYP3A4 and
CYP3A5 exons. Alphabetical order is used for PCR primers.
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occur in clinical practice. This effect reflects the possi-
bility that other active compounds can activate or inhibit
a particular isoenzyme, altering the biotransformation of
substrates. The inhibition of an enzyme that performs a
catabolic activity on a second one causes an increase in
plasma levels of the second, therefore prolonging its ac-
tion. The consequences can be particularly severe if the
inhibited enzyme is solely or primarily responsible for
the biotransformation of the drug. The inhibition of the
metabolism of a drug can also result in treatment failure
if its effectiveness resides in one or more metabolites
[1,3,4,6]. A typical example is the association of LPV/r:
Ritonavir competes with Lopinavir for the same cyto-
chrome P450 (CYP3A) isoenzyme but has a greater af-
finity, thus acting as a “booster”, increasing the plasma
half-life of LPV [16,17].
To date, the scientific community has paid great atten-
tion to the issue of human genetic variability in drug-
treated patients and its role in the occurrence of adverse
drug reaction (ADR), but little information is currently
available regarding whether CYP3A human gene expres-
sion profiles are predictive of adverse drug reactions(ADRs). Despite the fact that more than 60% of all li-
censed drugs interact with CYP3A, the real significance
of CYP3A SNPs has been only partially elucidated and
few, limited studies have been performed. In this light,
identifying mutations that can act as sentinels of ADR
occurrence is crucial for improving the criteria for the
selection of drugs administered to single patients. This is
even more relevant from a practical point of view, since
the methods for detecting SNPs in CYP3A sequence are
used solely for research purposes.
In this study, we sought to improve the performance
of a sensitive screening for CYP3A polymorphism detec-
tion. The novelty of this method relies on the improve-
ment of data accessibility by sequencing CYP3A4 and
CYP3A5 genes in a faster and less expensive way than
the traditional or commercially available methods.
Primarily, we reviewed the literature in similar popula-
tion based studies on the available methods for detecting
SNPs in the CYP3A gene. Real Time PCR or restriction
fragment length polymorphism (RFLP) were the most
used, providing analyses of only defined and small CYP3A
genomic areas, but lacked investigation of SNPs which are
not yet described [4,18,19]. Hence, we developed a simple,
Table 3 Frequency of CYP3A4 and CYP3A5
polymorphisms in 20 HIV-infected patients
Genotype/20 pts
Gene Polymorphism wt (n. pts) m (n. pts)
CYP3A4
CYP3A4*1B; 816 A > G 5′-flanking
region
17/20 3
CYP3A4*2; 15831 T < C exon 7 20
CYP3A4*4; 13989 A > G exon 5 20
CYP3A4*5; 15820 C > G exon 7 20
CYP3A4*6; 17775 insA exon 9 20
CYP3A4*8; 14026 G > A exon 5 20
CYP3A4*11; 21973 C > T exon 11 20
CYP3A4*12; 22002 C > T exon 11 20
CYP3A4*13; 22132 C > T exon 11 20
CYP3A4*16; 15721 C > G exon 7 20
CYP3A4*17; 15733 T > C exon 7 20
CYP3A4*18; 20178 T > C exon 10 20
CYP3A5
CYP3A5*3; 12083 G > A intron 3 17/20 3
CYP3A5*5; 18049 T > C intron 5 20
CYP3A5*6; 19787 G > A exon 7 20
CYP3A5*8; 8801 C > T exon 2 20
CYP3A5*9; 24483 G > A exon 10 20
CYP3A5*10; 34850 T > C exon 12 20
Wt: wild-type, m: mutated.
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litative PCR and subsequent sequencing of CYP3A (A4;
A5), including all exons and part of the intron region (see
Figure 1). This method, based on the sequence screening
of CYP3A4 and CYP3A5 genes may provide rapid, effec-
tive and comprehensive information on the molecular
analysis of CYP3A4 and CYP3A5 human variability.
The entire analysis, including the DNA purification,
preparation of the reaction mixture and PCR running
takes 9 hours. None of the reagents used in the PCR inter-
fere with the sequencing reaction; therefore, it is possible
to perform sequencing directly from PCR products. Its ap-
plication, aimed at optimizing diagnostic-therapeutic strat-
egies for managing different drugs in clinical practice, may
be useful for elucidating the genetic determinants of the
pathogenetic mechanisms related to ADR occurrence and
the role of unreported CYP3A SNPs.
Analysis of genes deputed to the metabolism of drugs,
when applied to patients who have shown ADRs, may be
the most comprehensive method for highlighting the
point mutation(s) that caused the reactions. In particular,
identifying CYP3A SNPs may also be helpful when se-
lecting the most appropriate antiretrovirals (PI used inHIV therapy) to be included in the first line regimen of
HIV-1 infected patients. They may contribute to minimi-
zing HIV resistance, reducing the general cost of anti-
retroviral therapy and avoiding ADR occurrence [7,20,21].
Among twenty HIV-positive patients undergoing LPV/r
monotherapy enrolled in this study, CYP3A4*1B was
found in two patients with treatment failure and de-
creased TDM of LPV. These data may suggest that the
presence of CYP3A4 SNPs, in particular the CYP3A4*1B
variant, may have a role in reducing LPV efficacy. How-
ever, this was a pilot analysis, therefore the method should
be evaluated in a larger set of patients.
In addition, our method is widely applicable to all
therapeutic regimens that include drugs metabolized by
CYP3A. Discovering new SNPs which can determine the
onset of ADR or affect treatment efficacy will allow for
the use of personalized therapeutic regimens that are
free from side effects. For example, immunosuppressant
drugs such as Tacrolimus (currently used in the manage-
ment of solid organ transplant recipients) are also exten-
sively metabolized by CYP3A isoenzymes [22-25]. In this
context, our study may also be useful for further analyzing
SNPs with significant influence on the metabolism and/or
inter-individual pharmacokinetic variability of Tacrolimus
in tranplants.Conclusions
Here we describe the development of a sequence screen-
ing method based on primer extension (with no additional
secondary steps as nested PCR) for rapid detection of
SNPs in the CYP3A4 and CYP3A5 gene sequence by
studying samples from patients undergoing therapy with
antiretroviral drugs metabolized via the CYP450 family.
Our method, which exhibited an overall efficiency of
100% (DNA amplification and sequencing in our group of
patients), may contribute to producing innovative results
for better understanding the inter-genotypic variability in
gene coding for CYP3A and investigating SNPs as bio-
logical markers of individual response to drugs requiring
metabolism via the cytochrome P450 system.Competing interests
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